Dr. Edward M. Kerwin, MD

Dr. Kerwin practices at Allergy & Asthma Center of Southern Oregon in Medford, Oregon.

Dr. Kerwin's NPI, 1568465847, was assigned on May 31, 2005. Dr. Kerwin graduated from University of Colorado School of Medicine, Denver in 1988. Dr. Kerwin holds Oregon license MD18405.

Dr. Kerwin's primary practice is Allergy & Asthma Center of Southern Oregon, at 3860 Crater Lake Ave, Medford, OR 97504 in Jackson County. The practice phone is (541) 858-1003.

Dr. Kerwin's primary practice is Allergy & Asthma Center of Southern Oregon in Medford, Oregon. The medical group on file is Allergy & Asthma Center of Southern Oregon. Dmand AI also links Dr. Kerwin to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kerwin practices. Vendor and product names are available with a free account.

Allergy is Dr. Kerwin's primary specialty in the NPI Registry, under taxonomy code 207KA0200X. Dr. Kerwin is licensed in Oregon.

CMS data shows 10,468 Medicare services from Dr. Kerwin across 9 procedure codes in 2024, for 283 Medicare patients. Medicare paid $120,926 for them. Every service was in an office.

CMS counts 283 Medicare patients who saw Dr. Kerwin in 2024. The largest group is 65 to 74, with 153 patients. 67% of them have high cholesterol, and 59% have high blood pressure. 6% are also on Medicaid. Their average risk score is 0.83, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kerwin's median patient age at 70, with 60% women.

In 2024, Dr. Kerwin wrote 511 Medicare Part D claims for 132 patients. 71% of them were for generic drugs. CMS names the drug for 401 of them, across 8 drugs with 11 or more claims each, at $44,369 in total drug cost. In 2023, CMS named 408 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 23 out of 100 for Dr. Kerwin for performance year 2024, reported individually. Dr. Kerwin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 99 papers to Dr. Kerwin, published from 2008 to 2025. 2019 was the busiest year, with 16. The most frequent topics are Bronchodilator Agents, Double-Blind Method and Pulmonary Disease, Chronic Obstructive. Dr. Kerwin has published most often in Int J Chron Obstruct Pulmon Dis. Dr. Kerwin's most frequent co-authors are Gary Thomas Ferguson, MD, David Andrew Lipson, MD and Paul Jones, MD.

Dmand AI links Dr. Kerwin to 14 clinical trials, 4 of them phase 3 studies. Conditions studied include Dermatitis, Atopic, Eczema and Asthma. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Kerwin that name 4 trials.

CMS Open Payments shows 433 general payments to Dr. Kerwin from 23 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 40% of the total. GlaxoSmithKline, LLC. paid the most, $48,348. It also lists 302 research payments totaling $978,235 from 2016 to 2022, naming 4 clinical trials.

Dr. Kerwin graduated from University of Colorado School of Medicine, Denver in 1988.